Source comparison
Sermorelin vs Exogenous GH: Comparative Research Data
The table below compares sermorelin-stimulated endogenous GH elevation to direct exogenous GH administration across key research parameters. Mechanism Stimulates pituitary somatotrophs via GHRH receptor activation Direct replacement. Bypasses pituitary entirel
This comparison does not assign a generated winner or score.
- The table below compares sermorelin-stimulated endogenous GH elevation to direct exogenous GH administration across key research parameters.
- Mechanism
- Stimulates pituitary somatotrophs via GHRH receptor activation
- Direct replacement. Bypasses pituitary entirely
- Sermorelin preserves feedback regulation; exogenous GH suppresses endogenous axis
- Pulsatility
- Maintains physiologic pulse amplitude and frequency
- Flattens pulsatile pattern. Constant receptor occupancy
- Pulsatile exposure required for normal GH receptor sensitivity in peripheral tissues
- IGF-1 Elevation
- +30–45% from baseline at 300–500 mcg nightly
- +40–60% from baseline at 2–4 IU daily
- Comparable IGF-1 outcomes, but sermorelin achieves this without axis suppression
- Axis Suppression Risk
- Minimal. Negative feedback remains intact
- High. 60–80% reduction in endogenous GH pulses within 6 weeks
- Exogenous GH creates dependency; sermorelin does not
- Washout Period
- Endogenous secretion resumes immediately upon cessation
- 4–8 weeks required for axis recovery post-cessation
- Critical difference for protocols requiring intermittent use or cycling
- Cost (research-grade)
- $180–$320 per 5 mg vial (10–25 doses at 200–500 mcg)
- $600–$1,200 per 36 IU kit (18–36 doses at 1–2 IU)
- Sermorelin provides comparable IGF-1 outcomes at 40–50% of exogenous GH cost